| Assessment Status | Rapid Review Complete |
| HTA ID | 20055 |
| Drug | Opicapone |
| Brand | Ongentys® |
| Indication | As adjunctive therapy to levodopa and DOPA decarboxylase inhibitors (L-DOPA+DDCI) in adults with Parkinson’s disease and end-of-dose motor fluctuations in patients not stabilised on such combinations. |
| Assessment Process | |
| Rapid review commissioned | 14/12/2020 |
| Rapid review completed | 18/01/2021 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends opicapone not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations January 2022.
